Эпидемия «нестероидной триады» (ожирение, диабет, метаболический синдром) и рак молочной железы
Abstract
About the Author
Л. БерштейнRussian Federation
References
1. Berstein L. M. Cancer of hormone-dependent tissues in the frame of main non-communicable diseases. St / Petersburg: Aesculap. 2009. 180 p.
2. Belyaev A.M., Manikhas G.M., Merabishvili V.M. /eds/. Malignant tumors in St.Petersburg and other administrative territories of the North-West Federal district of Russia: morbidity, mortality, prevalence rate, survival. Saint-Petersburg. 2016, p. 29.
3. Rahib L, Smith BD, Aizenberg R et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014. Vol. 74. P. 2913–2921.
4. IDF Diabetes Atlas. Eighth Edition. 2017 (Key messages & Resources). http://www.diabetesatlas.org (вход совершен 29.08.2018).
5. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AA, Isakov MA. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018. Vol. 21. P. 144–159.
6. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017. Vol. 390. P. 2627–2642.
7. Salinas-Martinez AM, Flores-Cortes LI, Cardona-Chavarria JM et al. Prediabetes, diabetes, and risk of breast cancer: a case-control study. Arch Med Res. 2014. Vol. 45. P. 432–438.
8. Kovalenko I.М., Berstein L.М. Comparative hormone-associated and clinical-morphological features of breast and endometrial cancer in patients with and without diabetes. Vopr. Onkol. 2017. Vol. 63. P. 752–757.
9. Goodwin PJ. Obesity and breast cancer – what’s new? Expert Rev Endocrinol Metab. 2017. Vol. 12. P. 35–43.
10. Zhao H, Wang J, Fang D et al. Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk. Horm Cancer. 2018. Vol. 9. P. 229–239.
11. Gershuni V, Li YR, Williams AD et al. Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res Treat. 2017. Vol. 163. P. 375–381.
12. Brouckaert O, Van Asten K, Laenen A et al. Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a crosssectional study. Breast Cancer Res Treat. 2018. Vol. 168. P. 189–196.
13. Primeau V, Coderre L, Karelis AD et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2011. Vol. 35. P. 971–981.
14. Berstein LM, Poroshina TE, Turkevich EA et al. Features of endometrial cancer in patients with ‘metabolically healthy’ versus ‘standard’ obesity: the decreasing frequency of metabolically healthy obesity. Future Sci OA. 2015. Vol. 1(4). P. FSO68.
15. Park YM, White AJ, Nichols HB et al. The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer. 2017. Vol. 140. P. 2657–2666.
16. Chan DS, Vieira AR, Aune D et al. Body mass index and survival in women with breast cancer-systematic literature review and metaanalysis of 82 follow-up studies. Ann Oncol. 2014. Vol. 25. P. 1901–1914.
17. Cho WK, Choi DH, Park W. et al. Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clin Breast Cancer. 2018 Apr 19. pii: S1526–8209(17)30765–6. doi: 10.1016/j.clbc.2018.04.010. [Epub ahead of print].
18. Guinan EM, Hussey J, McGarrigle SA. A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers. BMC Cancer. 2013 Vol. 13:138. doi: 10.1186/1471-2407-13-138.
19. Mayer EL. Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol Educ Book. 2013. P. 9–14.
20. Kogawa T, Fujii T, Fouad TM et al. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018. Jun 18. doi: 10.1007/s10549-018-4853-4. [Epub ahead of print].
21. Farr A, Stolz M, Baumann L et al. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. Breast. 2017. Vol. 33. P. 153–158.
22. Sendur MA, Aksoy S, Akoncy MB. et al. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptorpositive premenopausal breast cancer. Future Oncol. 2015. Vol. 11. P. 905–907.
23. Dilman VM. Metabolic immunodepression which increases the risk of cancer. Lancet. 1977; Vol. 2(8050). P. 1207–1209.
24. Berstein LM, Kovalevskij AY, Poroshina TE et al. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J Cancer. 2007. Vol. 121. P. 514–519.
25. Bershtein LM, Kovalevskii AIu, Poroshina TE et al. Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer. Vopr Onkol. 2008. Vol. 54. P. 294–302.
26. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesityassociated cancer. Clin Cancer Res. 2013. Vol. 19. P. 6074–6083.
27. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014. Vol.1842. P.446-462.
28. Lohmann AE, Pimentel I, Goodwin PJ. Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer. J Natl Cancer Inst. 2018 May 18. doi: 10.1093/jnci/djy080. [Epub ahead of print].
29. Mackenzie H, Markar SR, Askari A. Obesity surgery and risk of cancer. Br J Surg. 2018 Jul 13. doi: 10.1002/bjs.10914. [Epub ahead of print].
30. Bodmer M, Meier C, Krahenbuhl S et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010. Vol. 33. P. 1304–1308.
31. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol. 2010. Vol. 6. P. 1313–1323.
32. Sheng X, Parmentier JH, Tucci J et al. Adipocytes sequester and metabolize the chemotherapeutic daunorubicin. Mol Cancer Res. 2017. Vol. 15. P. 1704–1713.
Review
For citations:
. Malignant tumours. 2018;8(3s1):5-8. (In Russ.)